RenovaCare Strengthens FDA Program with Leading U.S. Regulatory Group and Significant Investment

Roseland, NJ – May 28th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that it has expanded its engagement with MCRA, the leading U.S. regulatory group for medical devices and biologics, to continue to advance the Company’s FDA program.